National and Kapodistrian University of Athens
Development, characterization and application of biocompatible co-polymers with cyclodextrins as carriers for nasal drug delivery in neurodegenerative diseases: in vitro, ex vivo and in vivo evaluation
Abstract
dc:descriptionParkinson’s disease (PAD) is one of the most prevalent neurodegenerative disorders, and current therapies are predominantly administered orally. However, oral delivery faces some limitations due to gastrointestinal (GI) and liver first-pass metabolism, plasma protein binding, as well as the presence of the blood-brain barrier (BBB), all of which reduce drug bioavailability and delay therapeutic onset in the brain. These challenges highlight the need for alternative delivery routes to improve drug bioavailability and enhance central nervous system (CNS) targeting.Intranasal (IN) administration has gained increasing attention as a non-invasive approach to overcoming these limitations. The direct anatomical connection between the olfactory epithelium and the CNS enables drug transport to the brain, making the nasal route particularly advantageous for molecules with poor BBB permeability.Furthermore, to improve the therapeutic efficacy of a drug in clinical practice, innovative drug delivery platforms need to be explored. Among them, formulations combining block copolymers with cyclodextrins (CDs) represent a novel class of drug carriers with several favorable characteristics, including high biocompatibility, enhanced drug-loading capacity, controlled or sustained release, improved colloidal stability, and superior permeability across biological barriers, enabling targeted delivery to specific tissues. Given these advantages, it was considered worthwhile investigating such systems in pharmacokinetic (PK) animal studies. The main objective and novelty of this PhD thesis involve the design and development of advanced drug delivery systems for nasal administration of ropinirole hydrochloride (RH) for managing PAD. The research focuses on exploring the combination of biocompatible block copolymers, commercially available Poloxamer 407 (P407) and synthetic poly(ethylene-oxide)-b-poly(e-caprolactone) (PEO-b-PCL) with CDs, namely methyl-β-CD (MβCD) and hydroxy propyl-β-cyclodextrin (HPβCD), and the surfactant Tween 80 (Tw80). These components are co-assembled to form a new class of advanced drug delivery systems.In this context, hybrid nasal drug delivery systems of polymer/Tw80/MβCD or polymer/Tw80/HPβCD were formulated. These systems create novel biomaterials and supramolecular structures with diverse morphologies, integrating the physicochemical and thermotropic properties of their components. This research also examined how variations in PEO-b-PCL composition influence physicochemical, morphological, drug-loading, and release properties. First, the colloidal dispersions of ternary systems (P407/Tw80/MβCD, P407/Tw80/HPβCD, PEO-b-PCL/Tw80/MβCD and PEO-b-PCL/Tw80/HPβCD) were fabricated using the thin-film hydration method. An extensive physicochemical and morphological characterization was conducted. Their biocompatibility was assessed by conducting in vitro cytotoxicity studies. RH-loaded systems were subsequently prepared using the same preparation protocol, with two optimized system-to-RH weight ratios, selected based on preformulation results. In vitro release and ex vivo mucosal permeation of RH were assessed using Franz cells under simulating pH and temperature conditions of the nasal cavity. Additionally, RH nasal lyophilized formulations containing the commercially available P407, Tw80, and βCD derivatives were prepared, including blends with mannitol/lecithin spray-dried microparticles (MLMPs). SEM was used to analyze powder morphology, and in vitro/ex vivo tests examined material interactions and the impact of MLMPs on morphological and biopharmaceutical properties. Finally, the serum and brain pharmacokinetics of the optimized formulations were further studied after IN administration in mice in comparison to the oral route. The presentation of the study’s results is structured into four Parts (A–D). In the first part, “Part A: Introduction & Study design”, the rational of the study and a description of the study protocols and methodology is given together with the study’s objectives. In “Chapter 1: Introduction”, the most recent developments in nasal drug delivery and PAD are discussed, as well as a review of the use of CDs, polymers, and mixed CD–block copolymer systems in drug delivery is given. In “Chapter 2: Study design and Methodology” an overview of the study design and the basic theoretical aspects of the methodologies applied for the study is described. Furthermore, each chapter of parts “B–D" of the present thesis contains specific information about the experimental procedures and equipment used, to allow the independent comprehension of their application at each stage of the study. In brief, in Chapter 2 the following methodologies used in this thesis are described: •Preformulation studies, physicochemical and morphological characterization of colloidal dispersions •Physicochemical and morphological characterization of powders •Non-compartmental pharmacokinetic analysis •Animal studies: pharmacokinetic studies •Sample collection and handling procedures •Statistical data analysis The second, third, and fourth parts of the study presentation (Parts B, C & D) are structured into chapters, and each chapter is organized to be read independently. More specifically: “PART B: Design, Development and Nasal delivery of Ropinirole Poloxamer 407/Tween 80/Cyclodextrin systems for Parkinson’s disease in C57BL/6J mice”, consists of three chapters. The first one describes the development, the extensive physicochemical, morphological characterization and in vitro/ex vivo evaluation of hybrid P407/Tw80/CD/RH colloidal dispersions for potential use in PAD (Chapter 3). The second one presents the further formulation of colloidal dispersions into nasal powders and the evaluation of their morphological and biopharmaceutical characteristics (Chapter 4). Last, Chapter 5 presents the determination of the RH PK parameters after the administration of the optimized P407/Tw80/CD/RH formulations in C57BL/6J mice, in comparison to the oral and IN administration of RH solutions. The chapters are structured as follows: Chapter 3: Fabricating Polymer/Surfactant/Cyclodextrin Hybrid Particles for Possible Nose-To-Brain Delivery of Ropinirole Hydrochloride: In Vitro and Ex Vivo EvaluationRH is a non-ergolinic dopamine agonist used to manage PAD, and it is characterized by poor oral bioavailability. This study aimed to design and develop advanced drug delivery systems composed of P407, a non-ionic surfactant (Tw80), and CDs (MβCD or HPβCD) for possible brain targeting of RH after nasal administration. The hybrid systems were formed by the thin-film hydration method, followed by an extensive physicochemical and morphological characterization. The in vitro cytotoxicity of the systems on HEK293 cell lines was also tested. In vitro release and ex vivo mucosal permeation of RH were evaluated using Franz cells under simulated nasal cavity conditions (pH 5.6, 34 °C). The results indicated that the diffusion-controlled drug release exhibited a progressive increase throughout the experiment, while a proof-of-concept experiment on ex vivo permeation through rabbit nasal mucosa revealed a better performance of the prepared hybrid systems in comparison to RH solution. The encouraging results in drug release and mucosal permeation indicate that these hybrid systems can serve as attractive platforms for effective and targeted nose-to-brain delivery of RH with a possible application in PAD. Based on these encouraging results, other formulation strategies and further studies were performed to evaluate the effect of dose and formulation on the in vitro release and ex vivo permeation of RH through rabbit nasal mucosa, as well as the in vivo serum and brain PK profiles of the developed formulations after nasal administration. Chapter 4: Advanced P407/Tw80/βCD based Nasal Powders of Ropinirole Hydrochloride for Possible Nose-to-Brain Delivery in Parkinson’s disease: Preparation and Comprehensive In Vitro and Ex Vivo EvaluationThis study focused on the development of lyophilized nasal powders of RH, composed of P407 triblock copolymer, surfactant Tw80 and derivatives of βCD [MβCD or HPβCD] for managing PD. The lyophilized compositions were produced by freeze-drying of the corresponding colloidal dispersions. The innovative aspect of this research lies in the integration of these diverse biomaterials to develop advanced drug delivery systems for nasal administration. The optimal lyophilized formulations were blended with spray-dried MLMPs in various ratios. The blending process resulted in powders with improved morphological characteristics, as evidenced by scanning electron microscopy analysis. Nasal powders were characterized through in vitro diffusion and ex vivo permeation studies. Finally, a comparison between the nasal powders and the corresponding colloidal dispersions was held. Results showed that the lyophilized powders had a superior release profile compared to colloidal dispersions, and blending with MLMPs further enhanced this effect. Ex vivo powders' permeation across rabbit nasal mucosa was found to be more efficient compared to pure RH solution. In particular, the lyophilized formulation of (P407/Tw80/HPβCD)/RH 10:5 blended with MLMPs (25:75) achieved 54.40 ± 3.30% permeation of the loading dose and a mass balance of 98.15 ± 1.61%. This study demonstrates the potential of these formulations for effective nose-to-brain drug delivery. Further in vivo PK studies were conducted to assess the performance of the optimal formulations in an appropriate animal model. Chapter 5: Nasal administration of Ropinirole loaded P407/Tw80/HPβCD systems in C57BL/6J miceNasal administration has emerged as an effective alternative for drug delivery to CNS, particularly in neurodegenerative diseases. RH is used as a monotherapy or as an adjunctive combination with levodopa for the management of PAD. However, RH undergoes extensive first-pass metabolism, thereby limiting the amount of drug reaching the CNS. The purpose of the present study was the determination of the PK parameters of RH when administered intranasally as colloidal dispersion [(P407/Tw80/HPβCD)/RH 10:5] and as a powder [(P407/Tw80/HPβCD)/RH 10:5 blended with MLMPs (25:75)] for brain targeting. In particular, the PK study was carried out in comparison with oral (per os) and IN administration of pure RH solution in C57BL/6J mice. The brain and serum distribution pharmacokinetics of the drug were studied applying the sparse sampling non-compartmental analysis (NCA). The PK profiles after IN and per os administration revealed the efficiency of IN administration in rapidly and effectively delivering RH, both to the CNS and bloodstream. The pre-eminence of the nasal formulations is witnessed by higher serum AUC and Cmax values after IN administration of formulations compared to the per os administration of RH solution. Notably, the IN administration of the RH powder resulted in the highest systemic bioavailability (Frel(Serum) = 1497%) and brain exposure (Frel(Brain) = 541%), suggesting a promising role for nasal delivery in targeting the CNS.“PART C: Design, Development and Nasal delivery of Ropinirole PEO-b-PCL/Tween80/Cyclodextrin systems for Parkinson’s disease in C57BL/6J mice” consists of two chapters. The first chapter describes the development, the extensive physicochemical and morphological characterization of hybrid PEO-b-PCL/Tw80/CD/RH colloidal dispersions, along with their in vitro and ex vivo evaluation for potential use in PAD. It further investigates how variations in PEO-b-PCL composition affect physicochemical properties, morphology, drug-loading capacity, and release behavior (Chapter 6). The second chapter of part C presents the determination of RH PK parameters following administration of a selected PEO-b-PCL/Tw80/CD/RH formulations in C57BL/6J mice compared to both oral and IN administration of the RH solution (Chapter 7). The chapters are organized as follows: Chapter 6: PEO-b-PCL/Tween 80/Cyclodextrin systems: from bioinspired fabrication to possible nasal administration of Ropinirole Hydrochloride The present work investigates the combination of biocompatible block copolymers PEO-b-PCL with CDs, namely MβCD and HPβCD, to design and develop complex co-assembled structures that represent a new class of advanced drug delivery systems. The systems were formed by the thin-film hydration method. An extensive physicochemical and morphological characterization was conducted using differential scanning calorimetry, light scattering techniques, microcalorimetry analysis (mDSC), high-resolution ultrasound spectroscopy (HR-US), surface tension measurements, fluorescence spectroscopy, cryogenic transmission electron microscopy images, and in vitro cytotoxicity evaluation. These innovative hybrid colloidal dispersions were found to be attractive candidates as drug delivery systems with unique properties by encompassing the physicochemical and thermotropic properties of both classes of materials. In vitro diffusion experiments under pH and temperature conditions that mimic those of the human nasal cavity consistently demonstrated an effective release of RH from the formulations, with a mass balance exceeding 90% in most cases. Particularly, systems containing a 5 mg/mL concentration of RH and HPβCD exhibited superior in vitro release characteristics resembling those of the RH solution (0.5 mg/mL, pH 5.6). Ex vivo permeation studies using the rabbit nasal mucosa as a barrier confirmed that the developed formulations significantly enhanced RH permeation compared to the pure RH solution (0.5 mg/mL, pH 5.6). Among all tested formulations, those containing HPβCD were more effective than those with MβCD in enhancing RH permeation, identifying them as the most promising candidates for further investigation. These promising results enhance the potential of these hybrid, cutting-edge systems for nasal drug delivery applications. Subsequent in vivo PK profiles in both serum and brain were investigated following the nasal administration of the optimally developed formulations. Chapter 7: Nasal administration of Ropinirole loaded PEO-b-PCL/Tw80/HPβCD systems in C57BL/6J miceIN administration has emerged as a promising drug delivery route, offering direct nose-to-brain transport, bypassing the BBB and first-pass metabolism, reducing enzymatic degradation, minimizing systemic exposure and peripheral side effects, and enabling more precise, rapid, and patient-friendly CNS targeting. Recent studies have demonstrated the potential of IN systems for PAD management. In this context, the aim of this study was to determine the PK parameters of RH, an antiparkinsonian drug, when administered intranasally as colloidal dispersion [(PEO-b-PCL/Tw80/HPβCD/RH) 10:5] for possible nose-to-brain delivery, in comparison to the per os and IN administration of control RH solution in C57BL/6J mice. The brain and serum distribution PK parameters derived using NCA sparse data methodology illustrated that F12 colloidal dispersion significantly enhanced both systemic and brain exposure of RH, achieving higher serum AUC and Cmax values. Compared to per os administration, IN delivery of the colloidal dispersion achieved markedly higher drug concentrations in serum and brain tissue, even with a 3-fold lower administered dose. It showed high systemic (Frel(Serum) = 1815%) and brain (Frel(Brain) = 363%) relative bioavailability, underscoring its potential as an IN delivery system for efficient CNS targeting. “Part D: General conclusions, study limitations and future work” recapitulates the key findings of the study, discusses the limitations of the study, and suggests avenues for future investigation.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Saitani, Elmina-Marina
- Σαϊτάνη, Ελμίνα-Μαρίνα
Subjects
dc:subject × 34- Υβριδικά συστήματα
- Ενδορινική χορήγηση
- Μεταφορά από τη ρινική κοιλότητα στον εγκέφαλο
- Υδροχλωρική ροπινιρόλη
- Νόσος του Πάρκινσον
- Νευροεκφυλιστικές παθήσεις
- Πολυμερή
- Κυκλοδεξτρίνες
- Επιφανειοδραστική ουσία
- Πολυξαμερές 407
- Πολυ(αιθυλενο-οξείδιο)-β-πολυ(ε-καπρολακτόνη)
- Μεθυλo-β-κυκλοδεξτρίνη
- Υδροξυπροπυλo-β-κυκλοδεξτρίνη
- Μικροσωματίδια μαννιτόλης/λεκιθίνης
- Hybrid systems
- Intranasal delivery
- Nose-to-brain delivery
- Ropinirole hydrochloride
- Parkinson’s disease
- Neurodegenerative diseases
- Polymers
- Cyclodextrins
- Surfactant
- Poloxamer 407
- PEO-b-PCL block copolymers
- Methyl-β-cyclodextrin
- Hydroxypropryl-β-cyclodextrin
- Mannitol/lecithin microparticles
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61666